Abstract
Cytochrome P450 (CYP) 2C9 is the principal isoform of the CYP2C subfamily in the human liver and is involved in the oxidation of several endogenous and xenobiotic compounds, including many therapeutic drugs. The metabolism of drugs by CYP2C9 can yield either safe or toxic products, which may be related to the recognition and binding modes of the substrates to this isoform. These interactions can be studied using in silico methods such as quantum chemistry, molecular dynamics and docking simulations, which can also be useful for predicting the structure of metabolites. In these types of studies, the ligand and the protein must be tridimensional models; thus, the protein can be built by homology modeling or retrieved from the Protein Data Bank. Therefore, the current review emphasizes the importance of using in silico methods to predict the metabolism of CYP2C9 because these computational tools have allowed the description of the principal characteristics of the active site of this isoform at the molecular level and the chemical properties of its ligands.
Keywords: Cytochrome P-450 (CYP), CYP2C9, docking simulations, drug metabolism, homology modeling, molecular dynamics simulations, ligands, in silico, Protein Data Bank
Current Drug Metabolism
Title: Molecular Modeling Used to Evaluate CYP2C9-Dependent Metabolism: Homology Modeling, Molecular Dynamics and Docking Simulations
Volume: 12 Issue: 6
Author(s): Jessica E. Mendieta-Wejebe, Jose Correa-Basurto, Erika M. Garcia-Segovia, Gisela Ceballos-Cancino and Martha C. Rosales-Hernandez
Affiliation:
Keywords: Cytochrome P-450 (CYP), CYP2C9, docking simulations, drug metabolism, homology modeling, molecular dynamics simulations, ligands, in silico, Protein Data Bank
Abstract: Cytochrome P450 (CYP) 2C9 is the principal isoform of the CYP2C subfamily in the human liver and is involved in the oxidation of several endogenous and xenobiotic compounds, including many therapeutic drugs. The metabolism of drugs by CYP2C9 can yield either safe or toxic products, which may be related to the recognition and binding modes of the substrates to this isoform. These interactions can be studied using in silico methods such as quantum chemistry, molecular dynamics and docking simulations, which can also be useful for predicting the structure of metabolites. In these types of studies, the ligand and the protein must be tridimensional models; thus, the protein can be built by homology modeling or retrieved from the Protein Data Bank. Therefore, the current review emphasizes the importance of using in silico methods to predict the metabolism of CYP2C9 because these computational tools have allowed the description of the principal characteristics of the active site of this isoform at the molecular level and the chemical properties of its ligands.
Export Options
About this article
Cite this article as:
E. Mendieta-Wejebe Jessica, Correa-Basurto Jose, M. Garcia-Segovia Erika, Ceballos-Cancino Gisela and C. Rosales-Hernandez Martha, Molecular Modeling Used to Evaluate CYP2C9-Dependent Metabolism: Homology Modeling, Molecular Dynamics and Docking Simulations, Current Drug Metabolism 2011; 12 (6) . https://dx.doi.org/10.2174/138920011795713670
DOI https://dx.doi.org/10.2174/138920011795713670 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Personalized Treatment of Obsessive-Compulsive Disorder: Radiology, EEG, Pharmacogenetics and Biochemistry
Current Pharmacogenomics and Personalized Medicine Do we Need a New Procedure for the Assessment of Adverse Events in Anti-migraine Clinical Trials?
Recent Patents on CNS Drug Discovery (Discontinued) Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Stress-Induced Oxidative Changes in Brain
CNS & Neurological Disorders - Drug Targets Proteome Profile of Extratemporal Structures in Amygdala Kindling Mesial Temporal Lobe Epilepsy Rat Model: A Preliminary Study
Current Proteomics Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design The Ability of MEAs Containing Cultured Neuroglial Networks to Process Information
Current Bioinformatics Editorial [Hot Topic: Modulation, Absorption and Delivery of Xenobiotics: The Synergic Role of CYP450 and P-gp Activities (Guest Editor: Nicola Antonio Colabufo)]
Current Drug Metabolism The Mechanism of Action of Salsolinol in Brain: Implications in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Activity-Dependent Release of Adenosine: A Critical Re-Evaluation of Mechanism
Current Neuropharmacology Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Pharmacological Treatment of Cannabis Dependence
Current Pharmaceutical Design Telmisartan Promotes Potential Glucose Homeostasis in Stroke-Resistant Spontaneously Hypertensive Rats via Peroxisome Proliferator-Activated Receptor γ Activation
Current Neurovascular Research Immune-Glutamatergic Dysfunction as a Central Mechanism of the Autism Spectrum Disorders
Current Medicinal Chemistry Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Homocysteine and Folate Therapy in Dialysis Patients
Letters in Drug Design & Discovery On Chemical Structures with Potent Antiepileptic/Anticonvulsant Profile
Mini-Reviews in Medicinal Chemistry Ontologies of Drug Discovery and Design for Neurology, Cardiology and Oncology
Current Pharmaceutical Design Effect of Hemodialysis on Pharmacokinetics of Ezogabine/Retigabine and its N-Acetyl Metabolite in Patients with End Stage Renal Disease
Current Clinical Pharmacology